Example searches

DXR Daxor Corporation

Daxor Corp. is a biotechnology company which develops and manufactures BVA-100 blood volume analyzer, an instrument that measures human blood volume. Its IDANT division provides autologous blood storage; and andrology services, such as semen analysis, sperm washing and general lab testing. The company was founded by Joseph Feldschuh in 1970 and is headquartered in New York, NY.

Company profile

Ticker
DXR
Exchange
NYSEAMERICAN
Website
www.daxor.com
CEO
Michael R. Feldschuh
Employees
Incorporated
New York
Location
New York
Fiscal year end
Dec 31
Sector
Health Technology > Medical Specialties
Industry (SIC)
Surgical & Medical Instruments & Apparatus
3M • Boston Scientific • Baxter International • Stryker • Becton Dickinson and • Teleflex • ResMed • Hill-Rom • Integra LifeSciences • Haemonetics ...
SEC CIK
0000027367
Corporate docs
IRS number
132682108

DXR stock data

(
)

Calendar

13 Mar 20
14 Aug 20
31 Dec 20

News

Company financial data Financial data

Quarter (USD) Dec 11 Sep 11 Dec 10 Sep 10
Revenue 369.83K 340.91K 361.37K 453.28K
Net income -1.49M -4.18M 2.27M 2.6M
Diluted EPS -0.35 -0.99 0.53 0.62
Net profit margin -403% -1227% 627% 575%
Operating income -1.01M -1.26M -1.53M -1.28M
Net change in cash 29.91K -28.03K -49.3K
Cash on hand 59.63K 29.71K 57.74K 107.04K
Cost of revenue 176.95K 149.38K 184.72K 185.74K
Annual (USD) Dec 11 Dec 10
Revenue 1.45M 1.58M
Net income -7.19M 4.97M
Diluted EPS -1.7 1.17
Net profit margin -497% 315%
Operating income -5.79M -5.66M
Net change in cash 1.88K
Cash on hand 59.63K 57.74K
Cost of revenue 652.51K 727.65K

Financial data from Daxor earnings reports

Recent insider trades

DXR insider ownership history Insider history
Date Owner Security Transaction Code 10b5-1 $Price #Shares $Value #Remaining
22 Jul 20 Edward Feuer DAXOR COMMON STOCK Sale back to company Dispose D No 19.21 1,500 28.82K 0
22 Jul 20 of Joseph Feldschuh Estate DAXOR CORPORATION COMMON STOCK Sale back to company Dispose D No 20 225,000 4.5M 2,549,455
29 Jun 20 Joy S. Goudie STOCK OPTIONS ( right to buy ) COMMON STOCK Grant Aquire A No 13.06 2,000 26.12K 2,000
25 Jun 20 Feldschuh Jonathan Adam STOCK OPTION COMMON STOCK Grant Aquire A No 14.11 20,000 282.2K 20,000
Data from 3, 4 and 5 filings. Stock values as filed, not updated for current price.

Institutional ownership Q4 2019

DXR institutional ownership history Ownership history
0.5% owned by funds/institutions
13F holders
 Current Prev Q Change
Total holders 5 4 +25.0%
Opened positions 1 0 NEW
Closed positions 0 1 EXIT
Increased positions 0 1 EXIT
Reduced positions 1 1 –
13F shares
 Current Prev Q Change
Total value 186K 198K -6.1%
Total shares 19.74K 20.51K -3.7%
Total puts 0 0
Total calls 0 0
Total put/call ratio – – –
Largest owners
 Shares Value Change
Renaissance Technologies 11.1K $104K 0.0%
Prelude Capital Management 7.1K $67K -21.3%
UBS UBS 1.16K $11K NEW
WFC Wells Fargo & Company 392 $4K 0.0%
Proequities 0 $0
Largest transactions
 Shares Bought/sold Change
Prelude Capital Management 7.1K -1.92K -21.3%
UBS UBS 1.16K +1.16K NEW
WFC Wells Fargo & Company 392 0 0.0%
Proequities 0 0
Renaissance Technologies 11.1K 0 0.0%
Data from 13F filings. Stock values as filed, not updated for current price. Long positions only.

Financial reports

View all
N-CEN
Annual report (registered investment company)
13 Mar 20
N-CSR
Certified annual shareholder report (management investment company)
28 Feb 20
N-CSRS
Certified semi-annual shareholder report (management investment company)
27 Aug 19
N-CEN/A
Annual report (registered investment company) (amended)
23 May 19
N-CSR/A
Certified annual shareholder report (management investment company) (amended)
22 May 19
N-CEN
Annual report (registered investment company)
18 Mar 19
N-CSR
Certified annual shareholder report (management investment company)
1 Mar 19
N-CSRS
Certified semi-annual shareholder report (management investment company)
24 Aug 18
N-CSR/A
Certified annual shareholder report (management investment company) (amended)
7 Mar 18
N-CSR
Certified annual shareholder report (management investment company)
1 Mar 18

Current reports

View all
8-K
Daxor Corporation Announces Pricing of $7.0 Million Registered Direct Offering
21 Jul 20
8-K
Daxor Announces Prospective Randomized Control Trial at Duke University Medical Center to Guide Volume Treatment In Heart Failure Patients
16 Jul 20
8-K
Daxor Announces Initiation of First-of-It’s-Kind Multicenter BVA-100® Study in Hospitalized Patients with COVID-19
15 Jul 20
8-K
Daxor Corporation Announces Appointment of Henry D. Cremisi, MD, FACP and Joy Goudie, Esq. to the Company’s Board of Directors
1 Jul 20
8-K
Other Events
6 May 20
8-K
Other Events
23 Apr 20
8-K
Departure of Directors or Certain Officers
28 Sep 18
8-K
Amendments to the Registrant's Code of Ethics, or Waiver of a Provision of the Code of Ethics
16 May 17
8-K
Departure of Directors or Certain Officers
16 Feb 17
8-K/A
Departure of Directors or Certain Officers
27 Sep 16

Registration and prospectus

POS EX
Additional exhibits for listing
31 Oct 18
RW
Registration withdrawal request
10 May 13
S-8
Registration of securities for employees
6 Jul 04
S-3
Shelf registration
18 Mar 98

Proxies

View all
DEF 14A
Definitive proxy
4 Jun 20
N-PX
Annual report of proxy voting record
30 Aug 19
DEFR14A
Revised proxy
3 Jun 19
DEF 14A
Definitive proxy
30 May 19
N-PX
Annual report of proxy voting record
10 Jul 18
N-PX/A
Annual report of proxy voting record (amended)
13 Jun 18
DEF 14A
Definitive proxy
22 May 18
DEF 14A
Definitive proxy
14 Nov 17
N-PX
Annual report of proxy voting record
30 Aug 17
N-PX/A
Annual report of proxy voting record (amended)
14 Sep 16

Other

View all
EFFECT
Notice of effectiveness
15 Jul 20
EFFECT
Notice of effectiveness
23 May 19
CORRESP
Correspondence with SEC
20 May 19
CORRESP
Correspondence with SEC
17 May 19
CORRESP
Correspondence with SEC
10 May 19
CORRESP
Correspondence with SEC
10 May 19
CORRESP
Correspondence with SEC
3 May 19
CORRESP
Correspondence with SEC
3 Apr 19
EFFECT
Notice of effectiveness
20 Aug 18
CORRESP
Correspondence with SEC
17 Aug 18

Ownership

View all
4
DAXOR / of Joseph Feldschuh Estate ownership change
3 Aug 20
4
DAXOR / Edward Feuer ownership change
3 Aug 20
3
DAXOR / of Joseph Feldschuh Estate ownership change
3 Aug 20
4
DAXOR / JAMES A LOMBARD ownership change
29 Jul 20
4
DAXOR / MARTIN S WOLPOFF ownership change
15 Jul 20
4
DAXOR / Bernhard Saxe ownership change
10 Jul 20
4
DAXOR / Henry D. Cremisi ownership change
9 Jul 20
4
DAXOR / Joy S. Goudie ownership change
9 Jul 20
3
DAXOR / Joy S. Goudie ownership change
9 Jul 20
3
DAXOR / Henry D. Cremisi ownership change
9 Jul 20

Patents

APP
Utility
Flow-through Quantitative Blood Collection Vial
30 Apr 20
A device is presented for storing, transporting, measuring, and collecting blood, having the properties of a precisely determined volume, the ability to be emptied or filled while connected to a continuous source (such as a supply of a drug, or the bloodstream of a patient), and a geometry suitable for the entire device to be placed in the counting chamber of a detector (such as the counting well of a gamma counter).
APP
Utility
Blood Volume Analyzer with Guidance
30 Apr 20
Systems and methods are provided for analyzing blood of a living being, and for presenting guidance for medical treatment.
APP
Utility
Whole Blood Volume Analyzer
30 Apr 20
Systems and methods are provided for measuring blood volume of a living being.